An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma-Reference-Cited by-同舟云学术

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma

Published:2011-07 Issue:7 Volume:22 Page:1622-1627
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Witzig T.E.,Vose J.M.,Zinzani P.L.,Reeder C.B.,Buckstein R.,Polikoff J.A.,Bouabdallah R.,Haioun C.,Tilly H.,Guo P.,Pietronigro D.,Ervin-Haynes A.L.,Czuczman M.S.

Funder

Celgene Corporation

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/22/7/1622/458762/mdq626.pdf

Reference32 articles.

1. Cancer statistics, 2009;Jemal;CA Cancer J Clin,2009

2. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma;Habermann;J Clin Oncol,2006

3. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

4. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma[see comments];Philip;N Engl J Med,1995

5. Improvement of overall survival in advanced stage mantle cell lymphoma;Herrmann;J Clin Oncol,2009

Cited by 363 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A mechanistic model of curative combination therapy explains lymphoma clinical trial results;2024-06-25

2. Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma;New England Journal of Medicine;2024-06-20

3. Racial disparities in the incidence and survival outcomes in diffuse large B‐cell lymphoma in adolescents and young adults;European Journal of Haematology;2024-06-18

4. Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules;Cancer Letters;2024-06

5. New Insights into First-Line Therapy in Diffuse Large B-Cell Lymphoma: Are We Improving Outcomes?;Journal of Clinical Medicine;2024-03-27